FDA
-
-
-
-
-
-
-
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
-
-
-
-
-
-
-
MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten
-
-
-
-
-
-
-
MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients
-
-
-
-
-
-
-
MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients
-
-
-
-
-
-
-
UPDATE: MyoKardia (MYOK) Appoints William Fairey as EVP and Chief Commercial Officer
-
-
-
-
-
-
-
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
-
-
-
-
-
-
-
MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
-
251,368 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All